Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
about
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastomaMVP and vaults: a role in the radiation responseOleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivoAdding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantlyIn Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) PeptideTargeting multidrug resistance in cancerAcquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expressionInhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasisFibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.Nuclear Multidrug Resistance-Related Protein 1 Is Highly Associated with Better Prognosis of Human Mucoepidermoid Carcinoma through the Suppression of Cell Proliferation, Migration and Invasion.Collateral sensitivity as a strategy against cancer multidrug resistance.Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.Alpinetin inhibits lung cancer progression and elevates sensitization drug-resistant lung cancer cells to cis-diammined dichloridoplatium.Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer.Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Therapeutic resistance in lung cancer.Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation.Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.Investigational ABC transporter inhibitors.Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.The role of microvesicles in cancer progression and drug resistance.Importance of ABCC1 for cancer therapy and prognosis.Cellular communication via microparticles: role in transfer of multidrug resistance in cancer.MRP1 and its role in anticancer drug resistance.Transcriptional regulation, stabilization, and subcellular redistribution of multidrug resistance-associated protein 1 (MRP1) by glycogen synthase kinase 3αβ: novel insights on modes of cadmium-induced cell death stimulated by MRP1.Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer.Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro.Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells.FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells.Clinical significance of P-glycoprotein and glutathione S-transferase π expression in gallbladder carcinoma.
P2860
Q24815638-7C427ED2-4A62-43F8-9311-997C40D23561Q26822652-113AA0FF-983C-405E-AB52-DBC4B3DA47FEQ26865123-8D7FC29A-45B5-42C3-A01B-495CBA982F05Q28478340-7ABCDB2C-B64C-4E7A-AE86-56955B06EE8DQ28545246-97EA85B8-9DDA-40B4-99F5-DCA223A3D788Q28550452-F5A847E1-8885-498F-9C7D-EEC107F9692BQ29616803-AA2A3CEA-AE27-4636-8478-DC817178623AQ30365571-00B6EBA1-9428-46DE-86EE-C71FC24AA6CDQ30404427-8E388796-AD8E-49F0-B93C-D31A5F3377D3Q33757125-1EEBDD4D-CC26-4D5E-ACB3-82DA43A798BAQ33783047-6031BEAF-B010-4D85-A48D-45F7140F359CQ33890597-DC4C2744-A144-4E73-BB6D-E8939A889775Q35909729-4C6CA015-A278-47EC-B83A-169656976E91Q35946556-BD7968E6-8552-4BC1-8C1B-1D34A5C11CD4Q35972500-12C7B703-901E-4AB1-8DB3-0898694AF25EQ36261926-BC50539A-5883-4E21-A271-DCE1EF8A32A6Q36307089-6C20DB86-37EC-42A4-83F3-E6672BFAC41EQ36370652-66CD29F8-0042-4A47-A08D-D92FB6A1A2BEQ36503102-266B6BB2-E7F5-4EC6-9164-787207D7DDCEQ36525551-6C5791E8-B866-4F73-B31F-D0C8140DA099Q36609767-497736ED-6D8E-45B8-8D22-5EB38DA1D0A8Q36779964-8A54F7B6-3F76-4434-B9C5-49540CC0D78FQ36788463-952DD99E-7137-4272-9CDB-09F1BCEC2569Q37042612-14F1C8A6-DDE7-43C6-8028-6DB7AC53FEBAQ37240065-91ED0F72-B466-456A-B05E-B55DB99AD4FEQ37636632-B8719947-919C-4A3D-926D-40ABD6F7A374Q38001734-ED580210-D2B4-4F6D-AEB9-89FD0DA2A7D8Q38071981-E34D54FF-7B13-4C65-982A-48428B696EE6Q38077244-43224A0C-9808-4670-AD41-84465F64A214Q38199535-CB22B463-F35E-49A6-B92E-6D812DC0E158Q38206278-9B27F10E-0D98-4576-BF27-B263DBDF4577Q38626237-06B2DA23-B442-43E3-B1C4-D614046EDAF8Q38951596-33F1A7BD-4367-41CB-9406-0496514490DCQ39316831-2EE71375-B23E-4DE3-AEEB-C3F2B15BE2FFQ39547831-31710906-5B38-4FA2-B88B-7DC833087177Q40144950-9BE1C3E2-DBBE-4003-85F4-1A2056CA7CB3Q40855352-E63A26D2-21D3-474A-B242-6FDB8562889FQ41587732-7563D1D0-395D-416B-B852-86453AE73D2BQ41612715-D266F44B-2D19-4729-A9CE-2177B6A01E24Q41761270-38DA4F6F-4AFE-4B63-8B82-A4A0A23111B1
P2860
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Multidrug resistance markers P ...... ncer: prognostic implications.
@en
Multidrug resistance markers P ...... ncer: prognostic implications.
@nl
type
label
Multidrug resistance markers P ...... ncer: prognostic implications.
@en
Multidrug resistance markers P ...... ncer: prognostic implications.
@nl
prefLabel
Multidrug resistance markers P ...... ncer: prognostic implications.
@en
Multidrug resistance markers P ...... ncer: prognostic implications.
@nl
P2093
P2860
P1476
Multidrug resistance markers P ...... ancer: prognostic implications
@en
P2093
Andrea Gsur
Elisabeth Steiner
H Cantonati
Michael Micksche
Peter Hollaus
Thomas Zidek
Ulrike Setinek
P2860
P2888
P304
P356
10.1007/S00432-004-0653-9
P577
2005-01-27T00:00:00Z